Get the Stockscreener App
215.31
3.06%
-6.79
After Hours:
215.31
Natera Inc stock is traded at $215.31, with a volume of 848.90K.
It is down -3.06% in the last 24 hours and up +4.13% over the past month.
Natera Inc is a diagnostic and research company with proprietary molecular and bioinformatics technology. The company's key product offerings include its Panorama Non-Invasive Prenatal Test (NIPT) which screens for chromosomal abnormalities of a fetus as well as in twin pregnancies, typically with a blood draw from the mother, Horizon Carrier Screening (HCS) to determine carrier status for a large number of severe genetic diseases that could be passed on to the carrier's children, Signatera molecular residual disease (MRD) test, which detects circulating tumor DNA in patients previously diagnosed with cancer to assess molecular residual disease and monitor for recurrence; and Prospera, to assess organ transplant rejection.
See More
Previous Close:
$222.10
Open:
$218.19
24h Volume:
848.90K
Relative Volume:
0.60
Market Cap:
$30.84B
Revenue:
$2.50B
Net Income/Loss:
$-226.32M
P/E Ratio:
-131.19
EPS:
-1.6412
Net Cash Flow:
$71.51M
1W Performance:
-3.61%
1M Performance:
+4.13%
6M Performance:
-11.96%
1Y Performance:
+30.09%
1-Day Range:
$214.82
$222.13
1-Week Range:
$204.16
$227.90
52-Week Range:
$131.81
$256.36
Natera Inc Stock (NTRA) Company Profile
Name
Natera Inc
Sector
Industry
Phone
650-249-9090
Address
13011 MCCALLEN PASS, AUSTIN, CA
Compare NTRA vs TMO, DHR, IDXX, A, WAT
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
NTRA
Natera Inc
|
215.31 | 31.81B | 2.50B | -226.32M | 71.51M | -1.6412 |
TMO
Thermo Fisher Scientific Inc
|
472.80 | 179.13B | 45.20B | 6.87B | 6.75B | 18.19 |
DHR
Danaher Corp
|
184.30 | 132.10B | 24.78B | 3.68B | 5.29B | 5.1743 |
IDXX
Idexx Laboratories Inc
|
562.16 | 44.55B | 4.45B | 1.10B | 1.06B | 13.59 |
A
Agilent Technologies Inc
|
135.44 | 39.08B | 7.23B | 1.41B | 1.09B | 4.979 |
WAT
Waters Corp
|
365.36 | 36.96B | 3.77B | 449.25M | 240.68M | 7.8556 |
Natera Inc Stock (NTRA) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-14-26 | Initiated | William Blair | Outperform |
| Jan-07-26 | Initiated | Citigroup | Buy |
| Dec-02-25 | Resumed | Morgan Stanley | Overweight |
| Oct-27-25 | Upgrade | BNP Paribas Exane | Underperform → Neutral |
| Sep-22-25 | Resumed | Wells Fargo | Equal Weight |
| Mar-13-25 | Initiated | RBC Capital Mkts | Outperform |
| Jan-23-25 | Initiated | Barclays | Overweight |
| Jun-03-24 | Resumed | Jefferies | Buy |
| Apr-08-24 | Resumed | Craig Hallum | Buy |
| Feb-20-24 | Downgrade | Raymond James | Strong Buy → Outperform |
| Dec-29-23 | Reiterated | BTIG Research | Buy |
| Dec-14-23 | Initiated | Guggenheim | Buy |
| Dec-13-23 | Initiated | Wolfe Research | Outperform |
| Nov-13-23 | Upgrade | Raymond James | Outperform → Strong Buy |
| Sep-28-23 | Initiated | Bernstein | Mkt Perform |
| Jul-05-23 | Resumed | JP Morgan | Overweight |
| May-05-23 | Initiated | UBS | Buy |
| Jan-18-23 | Upgrade | Raymond James | Mkt Perform → Outperform |
| Aug-25-22 | Initiated | Credit Suisse | Outperform |
| Apr-25-22 | Initiated | Stephens | Overweight |
| Mar-08-22 | Initiated | Goldman | Buy |
| Jan-06-22 | Resumed | Piper Sandler | Overweight |
| Oct-15-21 | Resumed | Cowen | Outperform |
| Jun-15-21 | Initiated | Raymond James | Mkt Perform |
| May-25-21 | Initiated | Wells Fargo | Overweight |
| Jan-28-21 | Initiated | Truist | Buy |
| Oct-08-20 | Initiated | BTIG Research | Buy |
| Sep-28-20 | Initiated | Morgan Stanley | Overweight |
| Sep-17-20 | Initiated | SVB Leerink | Outperform |
| Jun-10-20 | Resumed | Piper Sandler | Overweight |
| May-07-20 | Upgrade | JP Morgan | Neutral → Overweight |
| Oct-05-18 | Initiated | JP Morgan | Neutral |
| Jul-05-18 | Reiterated | Piper Jaffray | Overweight |
| Aug-07-17 | Reiterated | Morgan Stanley | Overweight |
| Nov-10-16 | Reiterated | The Benchmark Company | Buy |
| May-23-16 | Reiterated | The Benchmark Company | Buy |
| May-11-16 | Reiterated | The Benchmark Company | Buy |
| Apr-19-16 | Initiated | The Benchmark Company | Buy |
| Sep-28-15 | Upgrade | Wedbush | Neutral → Outperform |
| Aug-14-15 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Aug-04-15 | Initiated | Robert W. Baird | Outperform |
| Jul-27-15 | Initiated | Morgan Stanley | Equal-Weight |
| Jul-27-15 | Initiated | Piper Jaffray | Overweight |
| Jul-27-15 | Initiated | Wedbush | Neutral |
View All
Natera Inc Stock (NTRA) Latest News
5 Healthcare Stocks That the AI Crowd Is Overlooking - Barron's
Natera, Inc. Balance Sheet – XETR:45E - TradingView
Insider Sell Alert: Steven Chapman Sells 41,124 Shares of Natera Inc (NTRA) - GuruFocus
Natera CEO Steven Chapman sells $9.09 million in company stock By Investing.com - Investing.com South Africa
Natera CEO Steven Chapman sells $9.09 million in company stock - Investing.com UK
Natera(NTRA.US) Officer Sells US$9.09 Million in Common Stock - Moomoo
Natera (NTRA) CEO Chapman sells 41,124 shares under 10b5-1 plan - Stock Titan
(NTRA) as a Liquidity Pulse for Institutional Tactics - Stock Traders Daily
[144] Natera, Inc. SEC Filing - Stock Titan
Natera Expands Board, Appoints Thomas Lynch as Director - TipRanks
Natera (NTRA) appoints independent director Thomas Lynch and expands board - Stock Titan
Natera executive chairman sells $1.64m in shares - Investing.com
NTRA Initiates Coverage On Goldman Sachs -- Rating Set to Neutra - GuruFocus
NTRA & Diakonos partner to use Signatera in refractory melanoma trial - MSN
Natera, Inc. Earnings and Revenue – XETR:45E - TradingView
Natera to launch enhanced Panorama NIPT for low fetal fractions - MSN
Goldman Sachs initiates Natera stock with Neutral rating, $245 target - Investing.com UK
Goldman Sachs initiates Natera stock with Neutral rating, $245 target By Investing.com - Investing.com South Africa
Natera CytoDyn Signatera Pact Highlights Data Assets And Rich Valuation - simplywall.st
Natera partners with CytoDyn on cancer treatment research By Investing.com - Investing.com South Africa
Steven L. Chapman reports common‑share sales (NASDAQ: NTRA) - Stock Titan
CytoDyn (CYDY) Teams Up with Natera for Cancer Research Collaboration - GuruFocus
Natera and CytoDyn Announce Strategic Collaboration to Advance ctDNA-Guided Development and Molecular Response Analysis in Metastatic Colorectal Cancer - CytoDyn Inc.
Natera Inc stock (US6323071042): insider sales and new oncology board appointments in focus - AD HOC NEWS
Natera expands Austin operations with new sequencing facility - MSN
Natera, CytoDyn Partner in Colorectal Cancer Study - Contract Pharma
Natera partners with CytoDyn on cancer treatment research - Investing.com
DNA blood test to track tumors in new colon cancer drug trial - Stock Titan
Natera adds two oncology experts to board of directors - Investing.com UK
Insider Sell Alert: Solomon Moshkevich Sells 3,000 Shares of Nat - GuruFocus
Natera Appoints Oncology Leaders Drs. Thomas Lynch and Eric Rubin to Board of Directors - BioSpace
Natera president sells $655,294 of common stock - Investing.com
Natera (NTRA) clinical diagnostics president sells 3,000 shares under 10b5-1 plan - Stock Titan
Natera president sells $655,294 of common stock By Investing.com - Investing.com Canada
Natera(NTRA.US) Director Sells US$17.18 Million in Common Stock - Moomoo
Director Roelof Botha-linked vehicles sell 78K Natera (NTRA) shares - Stock Titan
Natera Adds Oncology Veterans Thomas Lynch and Eric Rubin to Board - citybiz
IVF Patients Say Natera Profited Off Ineffective Embryo Tests - Law360
Natera adds two oncology experts to board of directors By Investing.com - Investing.com Australia
Did Supreme Court’s Refusal to Hear Natera Appeal Just Shift CareDx’s (CDNA) Investment Narrative? - simplywall.st
NTRA Assumed by Wolfe Research -- Rating Upgraded to Outperform - GuruFocus
Wolfe Research initiates Natera stock coverage with outperform rating - Investing.com UK
Natera Inc stock (US6323071042): Wolfe Research initiation and recent price action in focus - AD HOC NEWS
Wolfe Research initiates Natera stock coverage with outperform rating By Investing.com - Investing.com South Africa
NTRA (NASDAQ: NTRA) insider sells multiple lots, files to resell 3,000 shares - Stock Titan
Natera Inc Stock (NTRA) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.84%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):